The COVID-19 pandemic created unprecedented disruption across the global pharma landscape. While it shed light on some systemic gaps in the sector, it also highlighted the growing focus on enhancing India's existing capabilities within generics, vaccines and APIs, and some emerging opportunities driven by progressive innovation and R&D. The report highlights key areas that underwent transformation as a result of the pandemic and outlines strategic recommendations for industry stakeholders to accelerate and catapult long-term growth for the Indian pharma industry.

Key Contact